Background {#Sec1}
==========

Cancer is a complex disease that develops as a result of the interactions between environmental factors and genetic inheritance. In 2012 there were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide \[[@CR1]\]. Endogenous or exogenous xenobiotics are activated or inactivated through two metabolic steps by phase I and phase II enzymes \[[@CR2]\]. The majority of chemical carcinogens require activation to electrophilic reactive forms to produce DNA adducts and this is mainly catalyzed by phase I enzymes. Although there are some exceptions, phase II enzymes, in contrast, detoxify such intermediates through conjugative reactions. The consequent formation of reactive metabolites and their binding to DNA to give stable adducts are considered to be critical in the carcinogenic process. It might therefore be expected that individuals with increased activation or low detoxifying potential have a higher susceptibility for cancer \[[@CR3]\].

Cytochrome P450 1A2 (CYP1A2) enzyme is a member of the cytochrome P450 oxidase system and is involved in the phase I metabolism of xenobiotics. In humans, the CYP1A2 enzyme is encoded by the *CYP1A2* gene \[[@CR4]\]. In vivo, CYP1A2 activity exhibits a remarkable degree of interindividual variations, as the gene expression is highly inducible by a number of dietary and environmental chemicals, including tobacco smoking, heterocyclic amines (HAs), coffee and cruciferous vegetables. Another possible contributor to interindividual variability in CYP1A2 activity is the occurrence of polymorphisms in the *CYP1A2* gene \[[@CR5]\], which have the potential for determining individual's different susceptibility to carcinogenesis \[[@CR6]\]. CYP1A2 is expressed mainly in the liver, but also, expression of the CYP1A2 enzyme in pancreas and lung has been detected. The *CYP1A2* gene consists of 7 exons and is located at chromosome 15q22-qter. More than 40 single nucleotide polymorphisms (SNPs) of the *CYP1A2* gene have been discovered so far \[[@CR7], [@CR8]\].

High in vivo CYP1A2 activity has been suggested to be a susceptibility factor for cancers of the bladder, colon and rectum, where exposure to compounds such as aromatic amines and HAs has been implicated in the etiology of the disease \[[@CR5], [@CR6]\]. Additionally, it has been reported that among the *CYP1A2* polymorphisms, *CYP1A2\*1C* (rs2069514) and *CYP1A2\*1 F* (rs762551) are associated with reduced enzyme activity in smokers \[[@CR5]\].

In recent years, efforts have been put into investigating the association of *CYP1A2* polymorphisms and the risk of several cancers, among them, colorectal \[[@CR9]--[@CR23]\], lung \[[@CR7], [@CR24]--[@CR32]\], breast \[[@CR33]--[@CR46]\], bladder \[[@CR4], [@CR47]--[@CR52]\], and other in different population groups, with inconsistent results. Therefore, with these meta-analyses we aimed to provide a quantitative assessment of the association between all *CYP1A2* polymorphisms and risk of cancer at various sites.

Methods {#Sec2}
=======

Selection criteria {#Sec3}
------------------

Identification of the studies was carried out through a search of MEDLINE, ISI Web of Science and SCOPUS databases up to February 15^th^, 2015, by two independent researchers (R.A. and V.V.). The following terms were used: \[(Cytochrome P450 1A2) OR (CYP1A2)\] AND (Cancer) AND (Humans \[MeSH\]), without any restriction on language. All eligible studies were retrieved, and their bibliographies were hand-searched to find additional eligible studies. We only included published studies with full-text articles available.

Also, detail search of several publically available databases of genome-wide association studies (GWAS) - GWAS Central, Genetic Associations and Mechanisms in Oncology (GAME-ON), the Human Genome Epidemiology (HuGE) Navigator, National Human Genome Research Institute (NHGRI GWAS Catalog), The database of Genotypes and Phenotypes (dbGaP), The GWASdb, VarySysDB Disease Edition (VaDE), The genome wide association database (GWAS DB), was carried out up to February 15^th^, 2015 for the association between *CYP1A2* and various cancers using the combinations of following terms: (Cytochrome P450 1A2) OR (CYP1A2) OR (Chromosome 15q24.1) AND (Cancer). Additional consultation of principal investigators (PI) of the retrieved GWAS was undertaken in order to obtain the primary data and include them in the analyses.

Studies were considered eligible if they were assessing the frequency of any *CYP1A2* gene polymorphism in relation to the number of cancer cases and controls, according to the three variant genotypes (wild-type homozygous (wtwt), heterozygous (wtmt) and homozygous mutant (mtmt)). Case-only and case series studies with no control population were excluded, as well as studies based only on phenotypic tests, reviews, meta-analysis and studies focused entirely on individuals younger than 16 years old. When the same sample was used in several publications, we only considered the most recent or complete study to be used in our meta-analyses. Meanwhile, for studies that investigated more types of cancer, we counted them as individual data only in a subgroup analysis by the tumour type, while when they reported different ethnicity or location within the same study, we considered them as a separate studies.

Data extraction {#Sec4}
---------------

Two investigators (C.I. and V.V.) independently extracted the data from each article using a structured sheet and entered them into the database. The following items were considered: rs number, first author, year and location of the study, tumour site, ethnicity, study design, number of cases and controls, number of heterozygous and homozygous individuals for the *CYP1A2* polymorphisms in the compared groups. We used widely accepted National Center for Biotechnology Information (NCBI) CYP classification \[[@CR53]\] to determine which specific genotype should be considered as wtwt, wtmt and mtmt. We also ranked studies according to their sample size, where studies with minimum of 200 cases were classified as small and above 200 cases as large.

Statistical analysis {#Sec5}
--------------------

The estimated Odds Ratios (ORs) and 95 % confidence interval (CI) for the association between each *CYP1A2* SNP and cancer were defined as follows:wtmt vs wtwt (OR~1~)mtmt vs wtwt (OR~2~).

According to the following algorithm on the criteria to identify the best genetic model \[[@CR54]\] for each SNP:Recessive model (mtmt versus wt carriers): if OR~2~ ≠ 1 and OR~1~ = 1Dominant model (mt carriers versus wtwt): if OR~2~ = OR~1~ ≠ 1,

we used the dominant model of inheritance for rs2069514, rs2069526 and rs35694136 and recessive model for rs762551, rs2470890 and rs2472304 in the meta-analysis. Random effect model was used to calculate the pooled ORs, taking into account the possibility of between studies heterogeneity \[[@CR55]\], that was evaluated by the χ^2^-based Q statistics and the *I*^*2*^ statistics \[[@CR56]\], where *I*^*2*^ = 0 % indicates no observed heterogeneity, within 25 % regarded as low, 50 % as moderate, and 75 % as high \[[@CR57]\]. A visual inspection of Begg's funnel plot and Begg's and Egger's asymmetry tests \[[@CR58]\] were used to investigate publication bias, where appropriate \[[@CR59]\]. To determinate the deviation from the Hardy-Weinberg Equilibrium (HWE) we used a publicly available program (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl> ). Additionally, the Galbraith's test \[[@CR60]\] was performed to evaluate the weight each study had on the overall estimate and its contribution on Q-statistics. We also performed a one-way sensitivity analysis to explore the effect that each study had on the overall effect estimate, by computing the meta-analysis estimates repeatedly after every study has been omitted.

Studies whose allele frequency in the control population deviated significantly from the Hardy-Weinberg Equilibrium (HWE) at the *p*-value ≤ 0.01 were excluded from the meta-analyses, given that this deviation may represent bias. We conducted stratified analysis by study design, ethnicity, sample size and tumour site to investigate the potential sources of heterogeneity across the studies. Statistical analyses were performed using the STATA software package v. 13 (Stata Corporation, College 162 Station, TX, USA), and all statistical tests were two-sided.

Results {#Sec6}
=======

Characteristics of the studies {#Sec7}
------------------------------

We identified a total of 2541 studies through MEDLINE, ISI Web of Science and SCOPUS online databases. One thousand and sixteen studies were left after duplicates removal, and after carefully reading the titles, only 175 studies were assessed for eligibility. After reviewing the abstracts, 120 full text articles were obtained for further eligibility. By not fulfilling the inclusion criteria, 61 full text articles were excluded, leaving 59 studies for quantitative synthesis. Additional hand-search of the reference lists of 59 included studies was done and 11 new eligible studies were found, resulting in 70 included studies.

Eleven GWASs on the association between *CYP1A2* SNPs and cancer risk were identified after detail search of GWAS online databases. Studies did not report full data on investigated SNPs, so we contacted principal investigators (PIs) to retrieve the information and include into our analyses. After 3 repeated solicitations, only one PI provided us with the full data on *CYP1A2* SNPs of breast cancer cases and controls, and by this making total of 71 studies included in our meta-analyses \[[@CR4], [@CR7]--[@CR52], [@CR61]--[@CR84]\]. Figure [1](#Fig1){ref-type="fig"} shows the process of literature search and study selection.Fig. 1Flowchart depicting literature search and study selection. \*GWAS data bases searched: GWAS Central, Genetic Associations and Mechanisms in Oncology (GAME-ON), the Human Genome Epidemiology (HuGE) Navigator, National Human Genome Research Institute (NHGRI GWAS Catalog), The database of Genotypes and Phenotypes (dbGaP), The GWASdb, VarySysDB Disease Edition (VaDE), The genome wide association database (GWAS DB)

Among the 71 included studies, 42 were population-based case-control studies, 28 hospital-based case-control studies and one genome-wide association study, including total of 47,413 cancer cases and 58,546 controls (Table [1](#Tab1){ref-type="table"}). The total investigated SNPs were six, of which 62 studies on the rs762551 \[[@CR4], [@CR7]--[@CR21], [@CR23], [@CR24], [@CR26]--[@CR46], [@CR48]--[@CR50], [@CR52], [@CR61]--[@CR65], [@CR67], [@CR68], [@CR72]--[@CR75], [@CR77]--[@CR79], [@CR81]--[@CR84]\]. Thirty five studies out of 62 were conducted on Caucasians (56.5 %), 17 on mixed populations (27.4 %) and 10 on Asians (16.1 %), including 33,181 cancer cases and 40,195 controls. Among them, 15 were on breast cancer, 14 studies on colorectal, and 9 on lung cancer.Table 1Description of 45 studies included in meta-analysis of association between different *CYP1A2* SNPs and cancerRs numberFirst authorYearTumour siteCountryEthnicitySample size (No. cases/controls)Crude OR° (95 % CI) recessive modelCrude OR (95 % CI) dominant modelrs762551Goodman MT. \[[@CR73]\]2001OvariesUSAMixed116/138\*^a^0.52 (0.19--1.43)--Sachse C. \[[@CR18]\]2002ColorectumUKCaucasian490/593\*ª1.15 (0.70--1.88)--Goodman MT. \[[@CR74]\]2003OvariesUSAMixed164/194\*ª0.73 (0.34--1.55)--Hopper J. \[[@CR36]\]2003BreastAustraliaCaucasian204/287\*^c^0.55 (0.27--1.13)--Doherty JA. \[[@CR68]\]2005EndometriumUSAMixed371/420\*ª1.27 (0.75--2.15)--Landi S. \[[@CR16]\]2005ColorectumSpainCaucasian361/321\*^b^**1.74 (1.05--2.88)**--Le Marchand L. \[[@CR39]\]2005BreastUSAMixed1339/1369\*^a^**0.73 (0.55--0.96)**--Prawan A. \[[@CR81]\]2005LiverThailandAsian216/233\*^a^0.52 (0.24--1.13)--Mochizuki J. \[[@CR79]\]2005LiverJapanAsian31/123\*^a^1.35 (0.26--7.01)--Agudo A. \[[@CR61]\]2006StomachEuropean countries^1^Caucasian242/943\*^a^0.88 (0.50--1.55)--Bae SY. \[[@CR9]\]2006ColorectumS. KoreaAsian111/93\*^b^1.14 (0.51--2.54)--De Roos AJ. \[[@CR67]\]2006LymphomaUSAMixed745/640\*^a^0.91 (0.63--1.31)--Li D. \[[@CR8]\]2006PancreasUSAMixed307/333\*^b^1.10 (0.65--1.84)--Long JR. \[[@CR41]\]2006BreastChinaAsian1082/1139\*^a^0.89 (0.71--1.13)--Rebbeck TR \[[@CR82]\]2006EndometriumUSAMixed475/1233\*^a^1.03 (0.73--1.46)--Kiss I. \[[@CR13]\]2007ColorectumHungaryCaucasian500/500\*^b^1.07 (0.74--1.54)--Kury S. \[[@CR15]\]2007ColorectumFranceCaucasian1013/1118\*^a^1.03 (0.75--1.41)--Osawa Y. \[[@CR29]\]2007LungJapanAsian103/111\*^a^1.17 (0.57--2.42)--Takata Y. \[[@CR46]\]2007BreastUSA (Hawaii)Mixed325/250\*^a^0.76 (0.39--1.49)--Yoshida K. \[[@CR23]\]2007ColorectumJapanAsian64/111\*^a^0.57 (0.21--1.53)--Gemignani F. \[[@CR26]\]2007LungEuropean countries^2^Caucasian297/310\*^b^0.86 (0.50--1.49)--Kotsopoulos J. \[[@CR38]\]2007BreastCanadaCaucasian170/241\*^b^**2.12 (0.99--4.57)**--Gulyaeva LF. \[[@CR35]\]2008EndometriumRussiaCaucasian166/180\*^a^2.20 (0.40--12.16)--Gulyaeva LF. \[[@CR35]\]2008OvariesRussiaCaucasian96/180\*^a^**9.21 (1.95--43.53)**--Gulyaeva LF. \[[@CR35]\]2008BreastRussiaCaucasian93/180\*^a^**27.58 (6.32--120.35)**--Hirata H. \[[@CR75]\]2008EndometriumUSACaucasian150/165\*^a^0.96 (0.62--1.51)--Saebo M. \[[@CR19]\]2008ColorectumNorwayCaucasian198/222\*^a^1.05 (0.49--2.23)--Suzuki H. \[[@CR84]\]2008PancreasUSACaucasian649/585\*^a^0.93 (0.56--1.54)--Figueroa JD \[[@CR48]\]2008BladderSpainCaucasian1101/1021\*^b^0.80 (0.62--1.04)--Zienolddiny S. \[[@CR32]\]2008LungNorwayCaucasian335/393\*^a^1.43 (0.88--2.32)--Cotterchio M. \[[@CR11]\]2008ColorectumCanadaCaucasian835/1247\*^a^0.91 (0.67--1.23)--Aldrich MC. \[[@CR7]\]2009LungUSAMixed113/299\*^a^**3.36 (1.58--7.13)**--Altayli E. \[[@CR4]\]2009BladderTurkeyCaucasian135/128\*^b^1.51 (0.88--2.60)--B'chir F. \[[@CR24]\]2009LungTunisiaCaucasian101/98\*^b^0.90 (0.47--1.70)--Kobayashi M. \[[@CR78]\]2009StomachJapanAsian141/286\*^b^0.62 (0.33--1.18)--Kobayashi M. \[[@CR14]\]2009ColorectumJapanAsian104/225\*^b^0.64 (0.31--1.32)--Shimada N (a) \[[@CR45]\]2009BreastJapan and BrazilAsian483/484\*^b^1.02 (0.71--1.47)--Shimada N (b) \[[@CR45]\]2009BreastBrazilMixed389/389\*^b^**0.50 (0.31--0.80)**--Sangrajrang S. \[[@CR44]\]2009BreastThailandAsian552/483\*^b^**2.72 (1.52--4.86)**--Villanueva C. \[[@CR52]\]2009BladderSpainCaucasian1034/911\*^b^0.82 (0.62--1.07)--Canova C. \[[@CR64]\]2009UADTEuropean countries^3^Caucasian1480/1437\*^b^0.88 (0.69--1.13)--Cleary SP \[[@CR10]\]2010ColorectumCanadaCaucasian1165/1290\*^a^0.93 (0.71--1.22)--Pavanello S. \[[@CR50]\]2010BladderItalyCaucasian155/161\*^b^0.57 (0.25--1.30)--Singh A. \[[@CR31]\]2010LungIndiaCaucasian200/200\*^a^**0.61 (0.37--1.00)**--The MARIE-GENICA Consortium \[[@CR43]\]2010BreastGermanyCaucasian3147/5485\*^a^1.04 (0.88--1.22)--Canova C. \[[@CR65]\]2010UADTItalyCaucasian376/386\*^b^1.21 (0.77--1.89)--Ashton KA \[[@CR62]\]2010EndometriumAustraliaCaucasian191/291\*^a^1.03 (0.71--1.49)--Guey LT \[[@CR49]\]2010BladderSpainCaucasian1005/1021\*^b^**0.77 (0.58--1.00)**--Rudolph A. \[[@CR17]\]2011ColorectumGermanyCaucasian678/680\*^a^1.38 (0.93--2.05)--Sainz J. \[[@CR20]\]2011ColorectumGermanyCaucasian1764/1786\*^a^0.95 (0.75--1.19)--Jang JH \[[@CR77]\]2012PancreasCanadaMixed447/880\*^a^1.08 (0.73--1.59)--Khvostova EP \[[@CR37]\]2012BreastRussiaCaucasian323/526\*^b^**1.82 (1.14--2.90)**--Pavanello S. \[[@CR30]\]2012LungDenmarkCaucasian421/776\*^a^**1.63 (1.08--2.48)**--Wang J. \[[@CR21]\]2012ColorectumUSAMixed305/357\*^a^0.97 (0.55--1.70)--Anderson LN \[[@CR33]\]2012BreastCanadaMixed886/932\*^a^**1.50 (1.09--2.07)**--Ayari I. \[[@CR34]\]2013BreastTunisiaCaucasian117/42\*^b^1.62 (0.51--5.11)--Barbieri RB \[[@CR63]\]2013Thyroid glandBrasilMixed123/339\*^a^**2.12 (1.16--3.87)**--Dik VK \[[@CR12]\]2013ColorectumThe NetherlandsCaucasian970/1590\*^a^1.10 (0.85--1.43)--Gervasini G. \[[@CR27]\]2013LungSpainCaucasian95/196\*^b^1.25 (0.60--2.61)--Lee HJ. \[[@CR40]\]2013BreastUSAMixed579/981\*^a^1.22 (0.85--1.75)--Lowcock E. \[[@CR42]\]2013BreastCanadaMixed1693/1761\*^a^1.24 (0.97--1.57)--Ghoshal U. \[[@CR72]\]2014StomachIndiaCaucasian88/170\*^a^1.13 (0.57--2.22)--Mikhalenko AP. \[[@CR28]\]2014LungBelarusCaucasian92/328\*^a^1.14 (0.44--2.93)--Shahabi A. \[[@CR83]\]2014ProstateUSAMixed1480/777\*^a^0.97 (0.72--1.30)--rs2069514Sachse C. \[[@CR18]\]2002ColorectumUKCaucasian60/73\*^a^--**12.71 (1.56--103.44)**Tsukino H. \[[@CR51]\]2004BladderJapanAsian306/306\*^a^--0.95 (0.69--1.31)Landi S. \[[@CR16]\]2005ColorectumSpainCaucasian328/295\*^b^--0.90 (0.38--2.10)Chiou HL \[[@CR25]\]2005LungChinaAsian162/208\*^b^--1.04 (0.69--1.57)Agudo A. \[[@CR61]\]2006StomachEuropean countries^1^Caucasian243/945\*^a^--1.66 (0.72--3.84)Chen X. \[[@CR66]\]2006LiverChinaAsian430/546\*^a^--0.97 (0.75--1.24)Bae SY. \[[@CR9]\]2006ColorectumS. KoreaAsian111/93\*^b^--0.68 (0.39--1.18)Yoshida K. \[[@CR23]\]2007ColorectumJapanAsian66/113\*^a^--0.82 (0.44--1.52)Osawa Y. \[[@CR29]\]2007LungJapanAsian106/113\*^a^--0.80 (0.46--1.36)Gemignani F. \[[@CR26]\]2007LungEuropean countries^2^Caucasian278/294\*^b^--0.52 (0.16--1.75)Zienolddiny S. \[[@CR32]\]2008LungNorwayCaucasian243/214\*^a^--0.65 (0.22--1.91)Imaizumi T. \[[@CR76]\]2009LiverJapanAsian209/256\*^a^--0.88 (0.61--1.27)B'chir F. \[[@CR24]\]2009LungTunisiaCaucasian101/98\*^b^--**5.88 (2.96--11.70)**Yeh CC \[[@CR22]\]2009ColorectumTaiwanAsian718/731\*^b^--1.08 (0.88--1.32)Gemignani F. \[[@CR71]\]2009PleuraItalyCaucasian92/643\*^b^--0.33 (0.04--2.45)Singh A. \[[@CR31]\]2010LungIndiaCaucasian200/200\*^a^--0.84 (0.47--1.50)Pavanello S. \[[@CR30]\]2012LungDenmarkCaucasian423/777\*^a^--0.85 (0.32--2.24)Ayari I. \[[@CR34]\]2013BreastTunisiaCaucasian109/41\*^b^--**0.35 (0.14--0.90)**Gervasini G. \[[@CR27]\]2013LungSpainCaucasian95/196\*^b^--2.67 (0.70--10.17)Cui X. \[[@CR47]\]2013BladderJapanAsian282/257\*^b^--0.89 (0.63--1.26)rs2069526Sachse C. \[[@CR18]\]2002ColorectumUKCaucasian490/593\*^a^--0.86 (0.60--1.22)Landi S. \[[@CR16]\]2005ColorectumSpainCaucasian321/288\*^b^--1.27 (0.55--2.90)Gemignani F. \[[@CR26]\]2007LungEuropean countries^2^Caucasian247/251\*^b^--**0.34 (0.14--0.81)**Zienolddiny S. \[[@CR32]\]2008LungNorwayCaucasian194/239\*^a^--1.66 (0.37--7.49)Gemignani F. \[[@CR71]\]2009PleuraItalyCaucasian78/579\*^b^--1.10 (0.42--2.90)Singh A. \[[@CR31]\]2010LungIndiaCaucasian200/200\*^a^--1.07 (0.65--1.75)Gervasini G. \[[@CR27]\]2013LungSpainCaucasian95/196\*^b^--1.36 (0.57--3.27)rs2470890Hopper J. \[[@CR36]\]2003BreastAustraliaCaucasian204/287\*^c^0.82 (0.47--1.43)--Landi S. \[[@CR16]\]2005ColorectumSpainCaucasian353/320\*^b^1.24 (0.84--1.82)--Chen X. \[[@CR66]\]2006LiverChinaAsian428/545\*^a^0.53 (0.27--1.06)--Kury S. \[[@CR15]\]2007ColorectumFranceCaucasian1013/1118\*^a^1.07 (0.90--1.27)--Gemignani F. \[[@CR26]\]2007LungEuropean countries^2^Caucasian283/298\*^b^0.83 (0.51--1.35)--Aldrich MC. \[[@CR7]\]2009LungUSAMixed113/299\*^a^1.12 (0.59--2.13)--Gemignani F. \[[@CR71]\]2009PleuraItalyCaucasian85/669\*^b^1.02 (0.56--1.88)--Canova C. \[[@CR64]\]2009UADTEuropean countries^3^Caucasian1455/1403\*^b^1.03 (0.84--1.26)--Canova C. \[[@CR65]\]2010UADTItalyCaucasian374/387\*^b^**1.51 (1.02--2.23)**--Anderson LN \[[@CR33]\]2012BreastCanadaMixed884/927\*^a^**1.49 (1.18--1.89)**--Eom SY. \[[@CR69]\]2013StomachS. KoreaAsian473/472\*^b^1.15 (0.55--2.37)--rs2472304Hopper J. \[[@CR36]\]2003BreastAustraliaCaucasian204/286\*^c^0.81 (0.46--1.43)--Sangrajrang S. \[[@CR44]\]2009BreastThailandAsian552/478\*^b^1.16 (0.59--2.29)--Aldrich MC. \[[@CR7]\]2009LungUSAMixed112/297\*^a^1.12 (0.59--2.14)--Ferlin A. \[[@CR70]\]2010TesticlesItalyCaucasian234/218\*^a^**0.68 (0.46--1.01)**--rs35694136Li D. \[[@CR8]\]2006PancreasUSAMixed307/329\*^b^--0.87 (0.63--1.18)Olivieri EH \[[@CR80]\]2009Head and NeckBrasilMixed81/134\*^b^--**8.98 (4.49--17.93)**Pavanello S. \[[@CR50]\]2010BladderItalyCaucasian167/141\*^b^--0.73 (0.46--1.14)Singh A. \[[@CR31]\]2010LungIndiaCaucasian200/200\*^a^--**1.65 (1.11--2.45)**Pavanello S. \[[@CR30]\]2012LungDenmarkCaucasian415/760\*^a^--0.98 (0.65--1.49)Ayari I. \[[@CR34]\]2013BreastTunisiaCaucasian108/38\*^b^--0.88 (0.40--1.93)Statistically significant results are presented in bold. °OR (95 % CI) Odds Ratio and 95 % Confidence Interval ^1^Ten European countries: Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom. ^2^Six European countries: Romania, Hungary, Poland, Russia, Slovakia, Czech Republic. ^3^Ten European countries: Czech Republic, Germany, Greece, Italy, Ireland, Norway, United Kingdom, Spain, Croatia, France. \*Hardy-Weinberg Equilibrium (HWE), *P* value ˃0.01. ^a^Population-based study ^b^Hospital-based study ^c^Genome-wide Association Study. (a), (b) One study with two different population

Twenty studies investigated the rs2069514 \[[@CR9], [@CR16], [@CR18], [@CR22]--[@CR27], [@CR29]--[@CR32], [@CR34], [@CR47], [@CR51], [@CR61], [@CR66], [@CR71], [@CR76]\], of which 11 were conducted on Caucasians (55 %) and 9 on Asians (45 %). Eight studies investigated the effect on lung cancer (40 %), 5 studies on colorectal cancer (25 %), 2 on liver cancer (10 %), 2 on bladder (10 %) and by 1 study on stomach (5 %), breast (5 %) and pleura (5 %), totaling for 4562 cancer cases and 6399 controls (Table [1](#Tab1){ref-type="table"}).

The remaining four SNPs were investigated by a reduced number of studies and details are presented in Table [1](#Tab1){ref-type="table"}. Genotype frequencies in all control groups did not deviate from values predicted by HWE (Table [1](#Tab1){ref-type="table"}). As some studies on different cancer types shared the same control group \[[@CR35]\], these studies were aggregated when performing the meta-analyses, except when stratified by tumour site.

Quantitative synthesis {#Sec8}
----------------------

As the crude analysis for rs762551 provided an OR~1~ of 1.03 (95 % CI 0.98--1.07) and an OR~2~ of 1.06 (95 % CI 0.97--1.16), for rs2470890 OR~1~ 1.03 (95 % CI 0.93--1.14) and OR~2~ of 1.14 (95 % CI 0.97--1.34) and for rs2472304 OR~1~ of 0.98 (95 % CI 0.79--1.22) and OR~2~ of 0.89 (95 % CI 0.66--1.22) according to the criteria proposed in the methods section, we applied the recessive model of inheritance for the meta-analyses. On the other hand, for rs2069514, rs2069526 and rs35694136 original papers did not report enough data to calculate OR1 and OR2, so we were able only to apply the dominant model for the data analyses.

The Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} depict the forest plots of the ORs of the six *CYP1A2* SNPs and cancer. By pooling 62 studies on rs762551, the meta-analysis reported an OR of 1.03 (95 % CI 0.96--1.12) for overall cancer (*P* for heterogeneity \< 0.01; *I*^*2*^ = 50.4 %). Egger test and the Begg's correlation method did not provide statistical evidence of publication bias (*P* = 0.19 and *P* = 0.39, respectively) (Fig. [4](#Fig4){ref-type="fig"}). To explore the potential sources of heterogeneity, we performed the Galbraith's test which identified the study of Shimada N. (b) \[[@CR45]\] and Sangrajrang S. \[[@CR44]\], as the main contributors to heterogeneity (graph not shown). In the one-way sensitivity analysis, these two outlying studies were omitted from meta-analysis and the overall OR slightly changed to 1.03 (95 % CI 0.96--1.11), with a reduced heterogeneity (*P* for heterogeneity \<0.01; *I*^*2*^ = 43.0 %).Fig. 2Forest plot of the *CYP1A2* rs762551 and cancer meta-analysis under recessive models of inheritance. The diamonds and horizontal lines correspond to the study-specific odds ratio (OR) and 95 % confidence interval (CI)Fig. 3Forest plot of the remaining five *CYP1A2* SNPs and cancer meta-analyses under different models of inheritance. The diamonds and horizontal lines correspond to the study-specific odds ratio (OR) and 95 % confidence interval (CI)Fig. 4Funnel plot for publication bias for studies with *CYP1A2* rs762551. Each point represents an individual study for the indicated association

Results of the stratified meta-analyses are reported in the Table [2](#Tab2){ref-type="table"}. When stratifying the results of meta-analysis for rs762551 by ethnicity, we found no significant effect of *CYP1A2* on cancer risk for Caucasians (OR = 1.03; 95 % CI 0.94--1.13), Asians (OR = 0.95; 95 % CI 0.72--1.27) nor among a mixed population (OR = 1.05; 95 % CI 0.89--1.25). When stratifying according to the tumour site, results showed an OR of 0.84 (95 % CI 0.70--1.01; *P* for heterogeneity = 0.23, *I*^*2*^ = 28.5 %) for bladder cancer for those homozygous mutant types of rs762551 (Table [2](#Tab2){ref-type="table"}). We further examined the association between the *CYP1A2* polymorphism and cancer risk according to ethnicity, source of controls and sample size and then stratified by cancer type. We found a significant OR of 0.79 (95 % CI 0.65--0.95; *P* for heterogeneity = 0.09, *I*^*2*^ = 58.1 %) for bladder cancer among the hospital-based population and among Caucasians. There was no significant association among Caucasians for breast cancer (OR = 1.71; 95 % CI 0.94--3.10; *P* for heterogeneity \< 0.01, *I*^*2*^ = 83.4 %), lung cancer (OR = 1.07; 95 % CI 0.79--1.44; *P* for heterogeneity = 0.07, *I*^*2*^ = 48.1 %,) or colorectal cancer (OR = 1.05, 95 % CI 0.94--1.16; *P* for heterogeneity = 0.49, *I*^*2*^ = 0.0 %). Among Asians, when stratifying for cancer type, we obtained an OR of 0.76 (95 % CI 0.47--1.22; *P* for heterogeneity = 0.48, *I*^*2*^ = 0.0 %) for colorectal cancer and OR = 1.27 (95 % CI 0.75--2.16; *P* for heterogeneity \<0.01, *I*^*2*^ = 83.6 %) for breast cancer.Table 2Subgroup meta-analyses of *CYP1A2* SNPs and cancer risk according to study design, ethnicity and tumour siteNumber cases/controlsRecessive modelExposedNot exposedOR°95 % CI°*I* ^*2*^ (%)*P* value for heterogeneityrs7625513373/400629,808/36,5621.030.96--1.1250.4\<0.01Study design Hospital based1048/11108289/84821.030.88--1.2060.3\<0.01 Population based2314/286921,326/27,8201.050.96--1.1541.8\<0.01Study sample size Large2883/338727,381/32,6801.020.94--1.1155.9\<0.01 Small490/6192427/38821.090.90--1.3236.00.05Ethnicity Asian348/4142539/28740.950.72--1.2754.60.02 Caucasian2132/260018,305/23,3881.030.94--1.1342.4\<0.01 Mixed893/9928964/10,3001.050.89--1.2562.8\<0.01Tumour site Bladder392/4363038/2806**0.840.70--1.01**28.50.23 Breast1097/128010,285/13,2691.170.94--1.4579.2\<0.01 Colorectum803/9347755/91991.030.93--1.140.00.56 Endometrium258/3911095/18981.060.87--1.300.00.85 Liver12/26235/3300.630.30--1.325.00.31 Lung221/2651536/24461.200.87--1.6458.90.01 Ovaries27/34349/4781.310.33--5.1980.30.01 Pancreas107/1421296/16561.040.80--1.360.00.87 Stomach46/141425/12580.850.59--1.210.00.45 UADT186/1921670/16310.970.73--1.2929.90.23Number cases/controlsDominant modelExposedNot exposedOR95 % CI*I* ^*2*^ (%)*P* value for heterogeneityrs20695141229/13733333/50260.990.81--1.2160.0\<0.01Study design Hospital based758/7831727/23291.010.73--1.4073.7\<0.01 Population based471/5901606/26970.940.78--1.1410.60.35Study sample size Large969/10852691/37360.970.86--1.090.00.89 Small260/288642/12901.180.65--2.1181.1\<0.01Ethnicity Asian1093/12351297/13880.960.86--1.070.00.86 Caucasian136/1382036/36381.160.63--2.1475.7\<0.01Tumour site Bladder236/237352/3260.920.73--1.170.00.81 Colorectum447/458836/8470.960.65--1.4353.20.07 Liver315/409324/3930.940.76--1.150.00.68 Lung211/2191397/18811.160.68--1.9976.3\<0.01Number cases/controlsDominant modelExposedNot exposedOR95 % CI*I* ^*2*^ (%)*P* value for heterogeneityrs2069526139/2021486/21440.940.70--1.2620.70.27Study design Hospital based35/78706/12360.890.47--1.7253.90.09 Population based104/124780/9080.940.71--1.250.00.59Study sample size Large121/1511137/11810.850.56--1.2849.40.12 Small18/51349/9631.290.71--2.350.00.89Ethnicity Caucasian139/2021486/21440.940.70--1.2620.70.27Tumour site Colorectum74/93737/7880.910.66--1.260.00.40 Lung60/75676/8110.900.47--1.7155.40.08Number cases/controlsRecessive modelExposedNot exposedOR95 % CI*I* ^*2*^ (%)*P* value for heterogeneityrs24708901106/11874559/55381.110.96--1.2839.00.09Study design Hospital based429/4802594/30691.100.95--1.270.00.46 Population based655/6701783/22191.090.80--1.5070.50.02Study sample size Large1077/10434390/47141.110.94--1.3050.90.04 Small29/144169/8241.070.69--1.660.00.85Ethnicity Asian28/42873/9750.770.37--1.6455.40.13 Caucasian863/9572904/35251.070.96--1.200.00.47 Mixed215/188782/1038**1.441.16--1.80**0.00.41Tumour site Breast222/189866/10251.170.65--2.0873.40.05 Colorectum500/509866/9291.100.94--1.280.00.51 Lung48/77348/5200.920.63--1.370.00.47 UADT294/2621535/15281.200.83--1.7465.70.09Number cases/controlsRecessive modelExposedNot exposedOR95 % CI*I* ^*2*^ (%)*P* value for heterogeneityrs2472304127/172975/11070.840.64--1.090.00.43Study design Population based85/120261/3950.820.51--1.3040.40.20Study sample size Large112/136878/8460.790.59--1.050.00.41Ethnicity Caucasian92/121346/383**0.720.52--0.99**0.00.61Tumour site Breast42/52714/7120.940.61--1.450.00.43Number cases/controlsDominant modelExposedNot exposedOR95 % CI*I* ^*2*^ (%)*P* value for heterogeneityrs35694136439/419839/11831.370.78--2.4289.0\<0.01Study design Hospital based290/263373/3791.460.56--3.7792.7\<0.01 Population based149/156466/8041.280.77--2.1368.40.08Study sample size Large290/319632/9701.110.75--1.6469.80.04 Small149/100207/2131.780.37--8.6094.6\<0.01Ethnicity Caucasian255/241635/8981.040.70--1.5362.00.05 Mixed184/178204/2852.730.28--27.0997.3\<0.01Tumour site Lung149/156466/8041.280.77--2.1368.40.08Statistically significant ORs are presented in bold. °OR (95 % CI) Odds Ratio and 95 % Confidence Interval

When pooling the 20 studies on rs2069514, the meta-analysis provided an OR of 0.99 (95 % CI 0.81--1.21) for overall cancer (*P* for heterogeneity \<0.01; *I*^*2*^ = 60 %) (Fig. [2](#Fig2){ref-type="fig"}). Egger test and the Begg's correlation method provided no statistical evidence of publication bias (*P* = 0.86 and *P* = 0.56, respectively). We performed the Galbraith's test to explore the source of heterogeneity and accordingly singled out the study of B'chir F. et al. \[[@CR24]\] as the main contributor to heterogeneity (graph not shown). In the one-way sensitivity analysis, the study of B'chir F. et al. \[[@CR24]\] was omitted from the overall meta-analysis and the heterogeneity dropped down to 14 % (*P* = 0.28), with the OR of 0.93 (95 % CI 0.82--1.06).

We evaluated the effect of the rs2069514 polymorphism according to the tumour site and obtained an OR of 0.96 (95 % CI 0.65--1.43; *P* for heterogeneity = 0.07, *I*^*2*^ = 53.2 %) for colorectal cancer, an OR of 1.29 (95 % CI 0.60--2.79; *P* for heterogeneity = 0.00; *I*^*2*^ = 82.1 %) for lung cancer (Table [2](#Tab2){ref-type="table"}). Analyses on different ethnicity and study design did not provide any significant results (Caucasians OR = 1.16; 95 % CI 0.63--2.14; *I*^*2*^ = 75.7 %, *P* \< 0.01, for Asians OR = 0.96; 95 % CI 0.86--1.07, *I*^*2*^ = 0.0 %; *P* = 0.86 and Hospital-based study design OR = 1.01; 95 % CI 0.73--1.40; *I*^*2*^ = 73.7 %, *P* \< 0.01, for Population-based design OR = 0.94; 95 % CI 0.78--1.14; *I*^*2*^ = 10.6 %, *P* = 0.35). We did not observe any significant association between rs2069514 polymorphism and cancer risk when subgrouping data according to ethnicity, source of controls and sample size and then stratified by cancer type. Among Caucasians, we obtained an OR of 1.28 (95 % CI 0.55--2.98; *I*^*2*^ = 80.9 %, *P* \< 0.01) for lung cancer, while among Asians OR = 0.94 (95 % CI 0.68--1.31; *I*^*2*^ = 0.0 %, *P* = 0.44) for lung and OR = 0.94 (95 % CI 0.71--1.24; *I*^*2*^ = 28.8 %, *P* = 0.25) for colorectal cancer.

We performed meta-analysis of 11 studies on rs2470890 which provided an OR of 1.11 (95 % CI 0.96-1.28) for the overall cancer risk (*P* for heterogeneity 0.09; *I*^*2*^ = 39 %) (Fig. [2](#Fig2){ref-type="fig"}). Egger test and the Begg's correlation method provided no statistical evidence of publication bias (*P* = 0.42 and *P* = 0.59, respectively). The Galbraith's test singled out the study of Anderson LN et al. \[[@CR33]\] as the main contributor to heterogeneity (graph not shown). In one-way sensitivity analysis, this study was omitted from the overall meta-analysis and the heterogeneity dropped down to 6 % (*P* = 0.39), with still not significant OR of 1.06 (95 % CI, 0.94--1.19). The effect of rs2470890 polymorphism according to the tumour site was also evaluated and was obtained non-significant result of OR of 1.10 (95 % CI, 0.94--1.28) *P* for heterogeneity = 0.51, *I*^*2*^ = 0.0 % for colorectal cancer and an OR of 1.20 (95 % CI, 0.83--1.74), *P* for heterogeneity = 0.09; *I*^*2*^ = 65.7 % for cancer of upper aero-digestive tract (UADT) (Table [2](#Tab2){ref-type="table"}). Subgroups analyses by different ethnicity showed a significant association between rs2470890 polymorphism and cancer for Mixed population OR = 1.44; 95 % CI 1.16--1.80; *I*^*2*^ = 0.0 %, P = 0.41, while not among Caucasians (OR = 1.07; 95 % CI 0.96--1.20; *I*^*2*^ = 0.0 %, *P* = 0.41) nor Asians (OR = 0.77; 95 % CI 0.37--1.64; *I*^*2*^ = 55.4 %, *P* = 0.13).

Results of the remaining three SNPs of *CYP1A2* are presented in the Fig. [3](#Fig3){ref-type="fig"} and the Table [2](#Tab2){ref-type="table"}. Absence of significant association with overall risk of cancer was reported. Only for rs2472304 we rendered an OR of 0.72 (95 % CI 0.52--0.99) *I*^*2*^ = 0.0 %, *P* = 0.61 for Caucasians, when doing a subgroup analyses on ethnicity. No evidence of significant heterogeneity was detected (data not shown).

When the meta-analyses were performed excluding small sample size studies for all examined SNPs, there were still no significant results obtained for the association between *CYP1A2* SNPs and cancer risk (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec9}
==========

The current meta-analysis included 71 studies with more than 47,000 cancer cases and 58,000 controls, detailing on all the *CYP1A2* gene polymorphisms and risk of cancer, shows no significant effect of investigated *CYP1A2* SNPs on cancer overall risk under various genetic models*.* Meta-analysis is a common tool for summarizing different studies to resolve the problem of small size statistical power and discrepancy in genetic association studies \[[@CR85]\] and also it provides more reliable results than a single case-control study. To the best of our knowledge, this is the largest and most comprehensive meta-analysis on *CYP1A2* SNPs and cancer performed so far. Several previous meta-analyses have been reported on the association between *CYP1A2* gene polymorphisms and risk of cancer \[[@CR86]--[@CR95]\]. Deng et al. \[[@CR87]\] reported no association between *CYP1A2* rs762551 polymorphism and lung cancer risk by including 1675 cases and 2393 controls. In the paper of Xue et al. \[[@CR94]\], combined mutational homozygous and wild type homozygous genotype compared with mutational heterozygous genotype, had protective effect against gastric cancer by including 383 cases and 1229 controls. Wen-Xia Sun et al. \[[@CR91]\] reported a significant protective effect of homozygous mutant of rs762551 *CYP1A2* SNP on bladder cancer in Caucasian population. Based on 19 studies, Wang et al. \[[@CR93]\] found a borderline significantly increased risk of overall cancer among homozygous mutant of *CYP1A2* rs762551, mainly in Caucasians. The meta-analysis of 46 case-control studies by Tian et al. \[[@CR92]\] suggested that the wild-type allele of *CYP1A2* rs762551 polymorphism might be associated with breast and ovarian cancer risk, especially among Caucasians. These inconclusive results could be explained by differences in study design, sample size, ethnicity, and cancer subtypes included.

The *CYP1A2* gene is a member of the CYP1 family and is involved in metabolism of carcinogens and estrogens. In particular, it plays an essential role in the metabolic activation of pro-carcinogens, such as polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines (HAA) \[[@CR93]\]. Therefore, increased levels of this enzyme could explain the association with increased risk for cancer \[[@CR16]\]. The wild genotype of *CYP1A2\*1 F* represents a highly inducible genotype, and this high CYP1A2 activity may increase the hydroxylated forms as proximate carcinogens, from HCAs and aryl-amines \[[@CR29]\].

In our meta-analyses, we showed that none of the investigated *CYP1A2* polymorphisms were significantly associated with overall risk of cancer at various sites. These results confirm the findings of a recent meta-analysis from Li Zhenzhen et al. \[[@CR95]\] where was reported no significant associations with cancer risk in any genetic model (allele contrast, codominant, dominant, or recessive model) in terms of rs2069514 and rs3569413. For rs762551, they found that carriers of C-allele have an increased overall risk of developing cancer in allele genetic model (C-allele vs. A-allele) while not in other models. Their further subgroup analyses demonstrated that rs762551 polymorphism was associated with an increased risk of cancer in Caucasians under dominant model, while we investigated rs762551 under recessive model and did not obtain significant association. Moreover, their meta-analysis included only 37 case-control studies of rs762551 involving 16,825 cancer cases and 21,513 controls. Our meta-analysis may be the most comprehensive meta-analysis of the relationship between the *CYP1A2* rs762551 polymorphisms and the risk of cancer, to date.

When stratifying according to tumour site, our results showed a borderline not significant OR of 0.84 (95 % CI, 0.70--1.01) for bladder cancer for those homozygous mutant of rs762551 with total of 3430 cases and 3242 controls included (Table [2](#Tab2){ref-type="table"}), thus confronting the previous evidence from Wen-Xia Sun et al. \[[@CR91]\] that reported an OR = 0.79 (95 % CI 0.66--0.94) from 2415 cases and 2208 controls, and suggesting that on even bigger number of subjects investigated, this significance might disappear. Pavanello et al. \[[@CR96]\] stressed that polymorphisms of rs762551 might be the crucial modulating factor along the continuum from the exposure to relevant environmental and occupational factors, in increased CYP1A2 activity of smokers measured by the urinary caffeine metabolic ratio.

We also found a significant decreased risk for bladder cancer for mutant carriers of rs762551 among the hospital-based population. Hospital-based studies have certain biases since those controls may have some benign diseases which can progress and also may not be representative of the general population. Using a population-based control would reduce the chance of bias in these studies.

In one recent meta-analysis by Zhi-Bin Bu et al. \[[@CR86]\] on the association between *CYP1A2* rs762551, rs2069514, rs2069526, and rs2470890 polymorphisms and lung cancer risk, there was no evidence of significant association between lung cancer risk and *CYP1A2* rs2069514, s2470890, and rs2069526 polymorphisms. They found increased lung cancer risk for rs762551 polymorphism in Caucasians from 3 studies, while in our analysis there was no such connection on a bigger sample of studies \[[@CR24], [@CR26]--[@CR28], [@CR30]--[@CR32]\].

Lastly, when stratifying our results for breast and colorectal cancer, we did not report any significant association between rs762551 and these cancers, thus confirming previous meta-analyses of Li-Xin Qiu et al. \[[@CR90]\] on breast and Xiao-Feng He et al. \[[@CR88]\] on colorectal cancer risk. Other meta-analysis by Jianbing Hu et al. \[[@CR89]\] also suggested that *CYP1A2* rs762551 polymorphism was not a risk factor for colorectal cancer susceptibility, since no association was detected after all studies were pooled together nor in a subgroup analysis by ethnicity or source of controls, in all genetic models. The influence of the different *CYP1A2* SNPs might be camouflaged by the presence of some yet unidentified causal genes involved in many other types of cancer.

When stratifying the results according to ethnicity, the protective effect of rs2472304 in our study was restricted only to Caucasians, while for rs2470890, we noticed an increased risk among a mixed population. A possible explanation for these results could be that the same polymorphisms may play different roles in cancer susceptibility in different ethnic populations as well as different tumour positions, due to a difference in genetic backgrounds, the environment they live in, lifestyle and migrations, which all may have a critical role in cancer pathogenesis \[[@CR97]\]. Also, some low penetrance genetic effects of single polymorphism could be determined by their interaction with other polymorphisms and/or a specific environmental exposure.

No other relevant results were reported for the remaining SNPs, however there were available only few studies regarding these associations, involving relatively small number of participants.

In interpreting the results, some limitations of our study should be considered. Firstly, only published studies were included, so there was space for publication bias, which in fact was confirmed by formal statistical tests. Secondly, the study size for most of the *CYP1A2* polymorphisms was limited to perform any meaningful subgroup analyses. Thirdly, it would have been valuable to stratify the results according to environmental effect modifiers, though this was not possible, as the original data sets were not available. Indeed, due to lack of access to original data used in included studies, our meta-analyses are based on the unadjusted data, so the effects might be confounded or modified by relevant covariates. Fourthly, beside breast cancer, there are no genome-wide association studies of the effects of *CYP1A2* polymorphisms on cancer risk. We were able to include only one breast cancer GWAS into our analyses, therefore our results might be affected by additional publication bias.

Despite these limitations, our meta-analyses also have some advantages. First, the statistical power of the analyses was noticeably increased as a huge number of cases and controls were pooled from different studies and has more statistical powerful than any single case-control study. Secondly, in our analyses, we included more studies than any previously published meta-analysis on the association between *CYP1A2* polymorphism and cancer risks and investigated 6 different *CYP1A2* SNPs.

Conclusions {#Sec10}
===========

In conclusion, our meta-analysis suggests that investigated *CYP1A2* polymorphisms are not associated with cancer susceptibility under various genetic models. In order to reach a more definitive conclusion, there is a necessity for further gene-gene and gene-environment interaction studies to be conducted on different populations and larger sample size, for diverse *CYP1A2* SNPs.
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